Pantoprazole improves glycemic control in type 2 diabetes: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 11, 2012, Pages

  Singh, Pawan Kumar ^a   Hota, Debasish ^a   Dutta, Pinaki ^a   Sachdeva, Naresh ^a   Chakrabarti, Amitava ^a   Srinivasan, Anand ^a   Singh, Inderjeet ^a   Bhansali, Anil ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PANTOPRAZOLE; PLACEBO; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; GASTRIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN METABOLISM; MALE; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84868618395     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1720     Document Type: Article

References (19)

1. Das SK, Elbein SC 2006 The genetic basis of type 2 diabetes. Cell Science 2:100-131
2. Ford ES, Li C, Little RR, Mokdad AH 2008 Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 31:102-104
3. Cowey SL, Quast M, Belalcazar LM, Wei J, Deng X, Given R, Singh P 2005 Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression. Cancer 103:2643-2653 (Pubitemid 40800546)
4. Rehfeld JF, Stadil F 1973 The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J Clin Invest 52:1415-1426
5. Rehfeld JF, Stadil F, Baden H, Fischerman K 1975 The enteral insulin-stimulation after Whipple's operation. Diabetologia 11:207-210
6. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC 2006 Increased islet β cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 49:2689-2696 (Pubitemid 44510793)
7. Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, Xu JM 2006 Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World J Gastroenterol 12:4750-4753 (Pubitemid 44269739)
8. Ligumsky M, Lysy J, Siguencia G, Friedlander Y 2001 Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 33:32-35 (Pubitemid 32613575)
9. Cadiot G, Vissuzaine C, Pospai D, Ruszniewski P, Potet F, Mignon M 1995 Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results. Gastroenterol Clin Biol 19:811-817
10. Koop H, Klein M, Arnold R 1990 Serum gastrin levels during longterm omeprazole treatment. Aliment Pharmacol Ther 4:131-138 (Pubitemid 20300401)
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
12. Mefford IN, Wade EU 2009 Proton pump inhibitors as a treatment method for type II diabetes. Med Hypotheses 73:29-32
13. Hove KD, Færch K, Bödvarsdóttir TB, Karlsen AE, Petersen JS, Vaag A 2010 Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis. Diabetes Res Clin Pract 90:e72-e74
14. Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R 2011 Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2:217-220
15. Rooman I, Lardon J, Bouwens L 2002 Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 51:686-690 (Pubitemid 34760176)
16. Bödvarsdóttir TB, Hove KD, Gotfredsen CF, Pridal L, Vaag A, Karlsen AE, Petersen JS 2010 Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 53:2220-2223
17. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
18. Peters A 2010 Incretin-based therapies: review of current clinical trial data. Am J Med 123:S28-S37
19. Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S 2000 Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastroenterol 6:789-792 (Pubitemid 32015791)